Clinical Trials
22 trialsCISPD-7
Zhejiang University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
National Cancer Institute (NCI)
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
University Health Network, Toronto
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
UNC Lineberger Comprehensive Cancer Center
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
California Cancer Consortium
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
Millennium Pharmaceuticals, Inc.